New Antibody-Azacitidine combo aims to boost remission in High-Risk blood cancer
NCT ID NCT07672769
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding bexmarilimab, an antibody that targets Clever-1, to standard azacitidine chemotherapy improves outcomes for adults with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS). Participants are randomly assigned to receive one of two doses of bexmarilimab plus azacitidine, or a placebo plus azacitidine. The main goal is to select the best dose of bexmarilimab for future studies based on both response and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bexmarilimab (an antibody targeting Clever-1) plus azacitidine
- What this could lead to
- If successful, this combination could improve remission rates and offer a new treatment option for people with higher-risk myelodysplastic syndromes.
- What could go wrong
- This is an early-phase trial with a small number of participants. The drug may not prove more effective than standard care, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGHER-RISK MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.